Enhancing the Efficacy of Immune Checkpoint Inhibitor Therapy Using a Novel Treatment Combination
September 05, 2018
September 05, 2018
PHILADELPHIA, Pennsylvania, Sept. 5 -- The Wistar Institute issued the following news release:
A combination of a novel inhibitor of the protein CK2 (Casein kinase 2) and an immune checkpoint inhibitor has dramatically greater antitumor activity than either inhibitor alone, according to research from The Wistar Institute that was published online in Cancer Research.
Immune checkpoint inhibitors have been approved to treat several types of cancer, including some types o . . .
A combination of a novel inhibitor of the protein CK2 (Casein kinase 2) and an immune checkpoint inhibitor has dramatically greater antitumor activity than either inhibitor alone, according to research from The Wistar Institute that was published online in Cancer Research.
Immune checkpoint inhibitors have been approved to treat several types of cancer, including some types o . . .